Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA)
- Neil R. Poulter, FRCP1,
- Peter S. Sever, FRCP1,
- Björn Dahlöf, MD2,
- Hans Wedel, PHD3 and
- for the ASCOT Steering Committee and the ASCOT Investigators
- 1Imperial College London, London, U.K.
- 2Sahlgrenska University Hospital/Östra, Gothenburg, Sweden
- 3Nordiska Hälsovårdshagskolan, Gothenburg, Sweden.
- Address correspondence to N.R. Poulter, International Centre for Circulatory Health, Imperial College London, National Heart and Lung Institute, Faculty of Medicine, 59 North Wharf Rd., St Mary's Campus, London W2 1PG, U.K. E-mail: n.poulter{at}imperial.ac.uk
Response to Tseng
We agree with current recomendations (1, 2) that the use of statins should be based on absolute risk rather than lipid levels. All those with diabetes and hypertension who are >50 years old and/or have had diabetes for ≥10 years are at ≥20% risk of a major cardiovascular event in the next 10 years and as such are above the currently recommended threshold for statin therapy (1, 2). …
